Welcome to our dedicated page for IRADIMED SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRADIMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRADIMED's regulatory disclosures and financial reporting.
IRadimed Corporation files its annual report describing a focused business developing MRI-compatible IV infusion pumps, patient vital-sign monitors and ferromagnetic detection devices used in hospital MRI environments.
For fiscal 2025, revenue was $83.8 million and income from operations was $26.1 million, an operating margin of about 31.2%. The company sells primarily through a U.S. direct sales force and international distributors, with the United States contributing 84% of revenue and devices accounting for 72% of revenue. Management highlights its new MRidium 3870 IV pump, 3880 monitor, and FMD1 detector, notes reliance on key suppliers, extensive FDA and international regulation, and outlines detailed risk factors, including product concentration, cybersecurity, competition, and supply-chain disruption.
IRADIMED CORP Chief Commercial Officer Jeff Chiprin reported an equity award of 1,150 restricted stock units (RSUs). These RSUs were granted under Iradimed Corporation's 2023 Equity Incentive Plan and carry no cash exercise price.
The RSUs convert into common stock on a one-for-one basis. They vest in three equal annual installments beginning on December 7, 2026, and upon each vesting date Mr. Chiprin will receive the corresponding number of common shares.
Iradimed Corp's chief financial officer John Glenn received a grant of 8,907 restricted stock units (RSUs). The RSUs were awarded under Iradimed Corporation's 2023 Equity Incentive Plan and convert into common stock on a one-for-one basis.
The award vests in three equal annual installments beginning on December 7, 2026. After vesting, Glenn will receive one share of common stock for each vested RSU, and he currently holds 8,907 RSUs directly following this grant.
IRADIMED CORP director Monty K. Allen reported an open-market sale of company stock. On 02/13/2026, he sold 1,000 shares of common stock in multiple trades at a weighted average price of $100.2563 per share. After this transaction, he directly owned 21,000 shares of IRADIMED CORP common stock.
A shareholder of Iradimed has filed a notice to sell 1,000 shares of common stock under Rule 144 through Raymond James on or around 02/13/2026, to be traded on NASDAQ. The filing lists an aggregate market value of 100,256.26 for the planned sale.
The 1,000 shares come from restricted stock units that vested on 12/07/2025 (95 shares) and 12/11/2025 (905 shares) as compensation for board service. The issuer had 12,722,377 shares outstanding when this notice was prepared.
Nine Ten Capital Management LLC and related reporting persons report beneficial ownership of iRadimed Corp common stock on a Schedule 13G/A Amendment No. 6. They disclose holding 428,477 shares, representing 3.4% of the common stock, as of December 31, 2025.
The filers report sole voting and sole dispositive power over these 428,477 shares. They certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iRadimed Corp.
IRADIMED CORPORATION reported record fourth quarter and full-year 2025 results, with revenue of $22.7 million in Q4, up 17%, and full-year revenue of $83.8 million, up 14% from 2024.
Q4 2025 net income rose to $6.4 million, or $0.50 per diluted share, a 25% year-over-year increase, while non-GAAP diluted EPS reached $0.54. For 2025, net income was $22.5 million, or $1.75 per diluted share, with non-GAAP diluted EPS of $1.93.
The board raised the regular quarterly cash dividend to $0.20 per share from $0.17, payable on March 6, 2026 to shareholders of record on February 23, 2026. Management guided 2026 revenue to $91.0–$96.0 million, GAAP diluted EPS of $1.90–$2.05, and non-GAAP diluted EPS of $2.06–$2.21, reflecting expectations for contributions from the next-generation 3870 MRI-compatible IV infusion pump.
IRADIMED CORP insider activity centers on trust-managed share sales linked to CEO Roger E. Susi. On January 26, 2026, the Phillip Susi 2008 Dynasty Trust sold 4,339 common shares at a weighted average price of $100.54 and 661 shares at $101.38, both under a pre-established Rule 10b5-1 trading plan adopted on June 16, 2025.
After these sales, that trust held 2,262,500 shares. The filing also lists 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with Susi expressly disclaiming beneficial ownership of the latter beyond his pecuniary interest.
IRADIMED CORP insider activity: A trust associated with CEO, President and Chairman Roger E. Susi reported three planned sales of common stock on January 20, 2026 under a Rule 10b5-1 trading plan adopted on June 16, 2025. The Phillip Susi 2008 Dynasty Trust sold 2,129 shares at a weighted average price of $101.03, 1,074 shares at $102.03, and 1,797 shares at $102.70. After these transactions, that trust held 2,267,500 shares of IRADIMED common stock. The filing also shows indirect holdings of 162,950 shares by the Roger E. Susi Revocable Trust and 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust, with the reporting person disclaiming beneficial ownership beyond his pecuniary interest.
IRADIMED Corp insider trusts reported planned stock sales. Trusts associated with CEO, President and Chairman Roger E. Susi sold a total of 5,000 shares of IRADIMED common stock on January 12, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.
The Phillip Susi 2008 Dynasty Trust sold 4,888 shares at a weighted average price of $97.43 and 112 shares at $98.15, leaving it with 2,272,500 shares indirectly reported. Additional indirect holdings reported include 162,950 shares held by the Roger E. Susi Revocable Trust and 2,062,500 shares held by the Matthew Susi 2008 Dynasty Trust, with beneficial ownership disclaimed except to the extent of pecuniary interest.